8-K: American Oncology Network to Voluntarily Delist from Nasdaq

American Oncology Network has announced its decision to voluntarily delist its Class A common stock and warrants from the Nasdaq Capital Market.

Summary

• American Oncology Network (AON) has decided to voluntarily delist its Class A common stock and warrants from the Nasdaq Capital Market.
• The decision was recommended by a special committee of the board, comprised of independent directors.
• The company intends to file a Form 25 with the SEC to delist its securities around May 31, 2024, with the last trading day expected around June 7, 2024.
• The delisting is due to factors including a lack of research coverage, an inactive trading market, and the high costs associated with Nasdaq listing requirements.
• AON expects its stock and warrants to be quoted on the OTC market after delisting, but there is no guarantee a broker will make a market.
• The company has a five-year revenue CAGR of 42% and has added 40 providers and four new practices year-to-date.
• AON reports a robust balance sheet with over $100 million in cash and short-term securities as of March 31, 2024.

Sentiment

Score: 4

Explanation: The delisting is a negative event, indicating a lack of market interest and high costs. However, the company's strong revenue growth and cash position provide some positive counterpoints.

Positives

• AON has demonstrated a strong five-year revenue CAGR of 42%.
• The company has added 40 providers and four new practices year-to-date.
• AON has a robust balance sheet with over $100 million in cash and short-term securities.
• The company has secured protections for common equity holders following the delisting, including potential acquisitions at a premium.

Negatives

• The company is delisting from Nasdaq due to a lack of research coverage and an inactive trading market.
• There is no guarantee that a broker will continue to make a market for the stock on the OTC market.
• The delisting will result in the loss of the benefits of being listed on a major exchange.

Risks

• The future liquidity of the company's securities is uncertain after delisting.
• There is a risk that the company may not achieve its growth expectations.
• Changes in the board of directors and executive management could impact the company.
• The company is dependent on its executive management team.
• There is no guarantee that a broker will continue to make a market in the common stock and warrants on the OTC market.

Future Outlook

The company expects its common stock and warrants to be quoted on the OTC market after delisting, but there is no guarantee a broker will make a market. The company also mentions potential acquisitions of outstanding equity securities at a premium.

Management Comments

• Todd Schonherz, Chief Executive Officer, stated that AON has delivered an impressive five-year revenue CAGR of 42% and continues to experience strong momentum.
• He also mentioned that while going public allowed them to raise growth capital, they believe delisting will better position them to maximize shareholder value.

Industry Context

The delisting of AON from Nasdaq reflects a trend of some smaller companies choosing to move to the OTC market to reduce costs and regulatory burdens. This can be a strategic move for companies that do not see the benefits of a major exchange listing outweighing the costs.

Comparison to Industry Standards

• Many smaller healthcare companies with limited trading volume and analyst coverage have chosen to delist from major exchanges to reduce costs.
• The move to the OTC market is not uncommon for companies seeking to reduce regulatory burdens and operating expenses.
• The 42% revenue CAGR is a strong performance metric, indicating significant growth in the oncology sector, however, the delisting suggests that the company's public market valuation was not reflecting this growth.

Stakeholder Impact

• Shareholders may experience reduced liquidity and price discovery for their shares.
• Employees may be impacted by the change in the company's public status.
• Customers and suppliers are unlikely to be directly impacted by the delisting.

Next Steps

• The company will file a Form 25 with the SEC to delist its securities.
• The company expects its securities to be quoted on the OTC market.
• The company will enter into a customary stockholders agreement with certain equityholders under certain circumstances.

Key Dates

Keywords

delisting, Nasdaq, OTC, American Oncology Network, AON, stock, warrants, revenue, oncology, healthcare